Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Serdemetan||JNJ-26854165|JNJ 26854165||p53 Activator 11||Serdemetan (JNJ-26854165) is a small molecule that regulates ABCA1 expression and inhibits cholesterol transport, resulting in activation of p53 and increased cell death in Tp53 wild-type and mutant cells (PMID: 23820125, PMID: 27999193).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 positive||Advanced Solid Tumor||sensitive||Serdemetan||Phase I||Actionable||In a Phase I trial, Serdemetan (JNJ-26854165) treatment increased Tp53 expression in tumor and surrogate tissue, resulted in partial response in 1.8% (1/57) and stable disease in 38.6% (22/57) of patients with advanced solid tumors (PMID: 21831953).||21831953|
|TP53 positive||breast cancer||sensitive||Serdemetan||Phase I||Actionable||In a Phase I trial, Serdemetan (JNJ-26854165) treatment induced a 102% increase of Tp53 expression in tumor tissue, resulted in partial response in a patient with breast cancer (PMID: 21831953).||21831953|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|